Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Its primary purpose is to program biology to generate optimal therapeutics for significant impact on human health, leveraging the Generate Platform, a therapeutic area and protein modality agnostic system. This platform integrates computational innovation with scalable biohardware in a fully-integrated design–build–test–learn loop to create proprietary data and differentiated molecular solutions. It engineers proteins against therapeutic targets, either from existing references or through de novo design, addressing challenges beyond traditional technologies. The platform has advanced computationally engineered proteins into human clinical testing, including GB-0895, an investigational long-acting anti-TSLP monoclonal antibody enrolling patients in pivotal Phase 3 trials for severe asthma. Generate Biomedicines, Inc. also advances oncology product candidates toward clinical stages. Operating at the intersection of machine learning, biological engineering, and medicine, the company focuses on protein-based modalities across multiple disease areas to transform drug discovery into systematic drug generation. Founded in 2018 and headquartered in Somerville, Massachusetts, it plays a key role in advancing AI-driven biotherapeutics in the healthcare sector.
$14.29
+$0.39 (+2.84%)
Live · 03:57 PM
The business is unprofitable at the operating level (-737.04% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 55.9% YoY with margins expanding 225.6pp.
ROIC dropped from -202.13% to -255.26%, capital efficiency is deteriorating. Negative free cash flow of -$204M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$32M
▲ +55.9% YoY
Net Income (TTM)
-$223M
▼ -22.9% YoY
Op. Margin
-737.04%
▲ +225.6pp YoY
ROIC
-255.26%
▼ -53.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$204M
▼ -68.4% YoY
Op. Cash Flow (TTM)
-$201M
▼ -70.4% YoY
Net Debt
-$153M
Net Cash Position
Cash & Equiv.
$221M
Continue Research
Generate Biomedicines (GENB)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Generate Biomedicines scores 48/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Generate Biomedicines scores 48 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -737.0% operating margin and a -255.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh GENB's valuation and scores 48/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.